Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity

BMC Neurology

Volumn 5, Issue , 2005, Pages

  Selim, Magdy ^a   Savitz, Sean ^a   Linfante, Italo ^b   Caplan, Louis ^a   Schlaug, Gottfried ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN INJURY; CALCULATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEART DISEASE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PERFUSION WEIGHTED IMAGING; PREDICTION; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TRANSIENT ISCHEMIC ATTACK; VOLUMETRY; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; METHODOLOGY; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; STROKE; TREATMENT OUTCOME;

EID: 26444588775     PISSN: 14712377     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-5-10     Document Type: Article

References (26)

1. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153
2. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870
3. Schlaug G, Benfield A, Baird AE, Siewert B, Lovblad KO, Parker RA, Edelman RR, Warach S. The ischemic penumbra: Operationally defined by diffusion and perfusion MRI. Neurology. 1999;53:1528-1537
4. Selim M, Fink JN, Kumar S, Caplan LR, Horkan C, Yi C, Linfante I, Schlaug G. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: Prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002;33:2047-2052
5. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35-41
6. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-879
7. Spilker J, Kongable G, Barch C, Braimah J, Brattina P, Daley S, Donnarumma R, Rapp K, Sailor S. Using the NIH Stroke Scale to assess stroke patients. The NINDS rt-PA Stroke Study Group. J Neurosci Nurs. 1997;29:384-92
8. Wilterdink JL, Bendixen B, Adams HP Jr, Wolson RF, Clarke WR, Hansen MD. Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute ischemic stroke (TOAST). Stroke. 2001;32:2836-2840
9. Schaller B. Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance. Neurosci Lett. 2005;377(3):206-211.
10. Arboix A, Cabeza N, Garcia-Eroles L, Massons J, Oliveres M, Targa C, Balcells M. Relevance of transient ischemic attack to early neurological recovery after nonlacunar ischemic stroke. Cerebrovasc Dis. 2004;18(4):304-311.
11. Wegener S, Gottschalk B, Jovanovic V, Knab R, Fiebach JB, Schellinger PD, Kucinski T, Jungehulsing GJ, Brunecker P, Muller B, Banasik A, Amberger N, Wernecke KD, Siebler M, Rother J, Villringer A, Weih M. MRI in Acute Stroke Study Group of the German Competence Network Stroke. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke. 2004;35(3):616-621.
12. Rossnagel K, Jungehulsing GJ, Nolte CH, Muller-Nordhorn J, Roll S, Wegscheider K, Villringer A, Willich SN. Out-of-hospital delays in patients with acute stroke. Ann Emerg Med. 2004;44(5):476-483.
13. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke. 2003;34:2922-2929.
14. Daugherty A, Manning WM, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612
15. Yoshimoto T, Fukai N, Sato R, Sugiyama T, Ozawa N, Shichiri M, Hirata Y. Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells. Endocrinology. 2004;145:3331-3337
16. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 1999;100:1223-1229
17. Skurk T, Van Harmelen V, Hauner H. Angiotensin II Stimulates the Release of Interleukin-6 and Interleukin-8 From Cultured Human Adipocytes by Activation of NF-{kappa}B. Arterioscler Thromb Vasc Biol. 2004;24(7):1199-1203
18. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1623-1629
19. Michel JB. Renin-angiotensin system and vascular remodelling. Med Sci (Paris). 2004;20:409-413
20. Francis GS. ACE inhibition in cardiovascular disease. N Engl J Med. 2001;342:201-202
21. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, Votteas VV, Kyriakidis MK. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens. 2000;13:783-788
22. Walters M, Muir S, Shah I, Lees K. Effect of Perindopril on Cerebral Vasomotor Reactivity in Patients With Lacunar Infarction. Stroke. 2004;35: 1899-1902.
23. Chao CL, Lee YT. Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment. Stroke. 2000;3:2907-2911.
24. Mitsias PD, Jacobs MA, Hammoud R, Pasnoor M, Santhakumar S, Papamitsakis NI, Soltanian-Zadeh H, Lu M, Chopp M, Patel SC. Multiparametric MRI ISODATA ischemic lesion analysis: correlation with the clinical neurological deficit and single-parameter MRI techniques. Stroke. 2002;33:2839-2844
25. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke. Neurology. 1998;50:864-870
26. Fink JN, Selim MH, Kumar S, Silver B, Linfante I, Caplan LR, Schlaug G. Is the association of National Institutes of Health Stroke Scale scores and acute magnetic resonance imaging stroke volume equal for patients with right- and left-hemisphere ischemic stroke? Stroke. 2002;33(4):954-958